Hyperthermic Intraperitoneal Chemotherapy

Cancer treatment frequently requires a multimodality approach, involving surgical resection(s), radiotherapy, and chemotherapy. Advanced surgical approaches allow for the combination of two of these, offering patients intraoperative radiotherapy with surgical resection or intraoperative chemotherapy targeted and limited to a particular body region. The systemic toxic effect on nontargeted organs is always a concern in chemotherapy treatment. This potential limitation canminimize the dosage to that less than necessary for killing the intended malignancy. One option for overcoming this problem is administration of chemotherapy in a regionally limited method, which would expose the tumor to high drug concentrations yet reduce systemic exposure. In recent years, the practice of cytoreductive surgery combined with hyperthermic chemotherapy applied regionally has advanced as a treatment for cancermanagement. The incorporation of a hyperthermic variable improves the efficacy of numerous regionally administered chemotherapeutic agents. Malignant cells show a selective sensitivity to hyperthermia, and various causes have been hypothesized. On a cellular level, the tumor cells’ oxidative metabolism is inhibited, resulting in a lower pH and, in turn, an increase in lysosomal activity and cell death. In addition, membrane protein denaturation and an increase in vascular permeability may